Montelukast in Chronic Spontaneous Urticaria Guidelines
Montelukast is no longer recommended as a line of treatment in the most recent 2022 international urticaria guidelines, representing a significant change from previous versions. 1
Key Guideline Changes
The 2022 international urticaria guideline update explicitly removed leukotriene receptor antagonists (LTRAs), including montelukast, from the treatment algorithm. 1 This represents a major departure from earlier versions where montelukast was listed as a third-line option alongside omalizumab and cyclosporine. 1
Current Evidence-Based Treatment Algorithm
First-Line Treatment:
- Standard-dose second-generation H1-antihistamines as monotherapy 2, 3
- Options include cetirizine, desloratadine, fexofenadine, levocetirizine, loratadine, bilastine, rupatadine, and ebastine 3
Second-Line Treatment (if inadequate control after 2-4 weeks):
Third-Line Treatment (if up-dosing fails):
- Add omalizumab 300mg subcutaneously every 4 weeks 2, 3
- Allow up to 6 months for response assessment 2, 3
Fourth-Line Treatment (if omalizumab inadequate after 6 months):
- Add cyclosporine (up to 5mg/kg body weight) to H1-antihistamines 2, 3
- Monitor blood pressure and renal function every 6 weeks 2
Why Montelukast Was Removed
The removal of montelukast from the updated guidelines reflects the lack of high-quality evidence supporting its efficacy in chronic spontaneous urticaria. 4 While older guidelines suggested montelukast as a third-line option, research has consistently shown it has lower efficacy compared to omalizumab and cyclosporine. 4
Limited Supporting Evidence
The available research on montelukast shows mixed and modest results:
- One retrospective study found only 48% of patients responded to montelukast as add-on therapy 5
- A double-blind crossover trial showed no significant benefit in the overall population, with possible benefit only in a small subgroup with the most severe disease 6
- A small case series reported good response in only 4 of 9 patients 7
These studies are limited by small sample sizes, retrospective designs, and lack of robust placebo-controlled data. 4, 5, 6
Clinical Practice Implications
The current standard of care does not include montelukast in the treatment algorithm for chronic spontaneous urticaria. 1, 2 The American Academy of Allergy, Asthma, and Immunology guidelines align with the international consensus, recommending the stepwise approach of antihistamines → up-dosed antihistamines → omalizumab → cyclosporine. 2, 3
Important Caveats
While some older sources mention montelukast as a potential adjunctive therapy, 3 this recommendation predates the 2022 guideline update that removed it from the algorithm. 1 The evidence for montelukast monotherapy is particularly limited. 3
If considering montelukast in clinical practice despite its removal from guidelines, it should only be as an adjunctive therapy in highly selected patients who have failed standard treatments, not as a formal line of therapy. 4 However, omalizumab and cyclosporine have far superior evidence and should be prioritized. 4, 8
Neuropsychiatric Safety Concerns
Clinicians should also be aware that various neuropsychiatric events have been reported as adverse events with leukotriene receptor antagonists, though the evidence of association remains conflicting. 9